KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Liabilities and Shareholders Equity: 2018-2025

Historic Liabilities and Shareholders Equity for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $562.8 million.

  • Castle Biosciences' Liabilities and Shareholders Equity rose 9.37% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 11.85%. This contributed to the annual value of $531.2 million for FY2024, which is 17.18% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Liabilities and Shareholders Equity is $562.8 million, which was up 3.31% from $544.7 million recorded in Q2 2025.
  • Castle Biosciences' Liabilities and Shareholders Equity's 5-year high stood at $562.8 million during Q3 2025, with a 5-year trough of $425.4 million in Q2 2023.
  • For the 3-year period, Castle Biosciences' Liabilities and Shareholders Equity averaged around $485.7 million, with its median value being $487.3 million (2024).
  • As far as peak fluctuations go, Castle Biosciences' Liabilities and Shareholders Equity surged by 263.66% in 2021, and later dropped by 7.19% in 2023.
  • Over the past 5 years, Castle Biosciences' Liabilities and Shareholders Equity (Quarterly) stood at $462.6 million in 2021, then dropped by 3.30% to $447.3 million in 2022, then rose by 1.34% to $453.3 million in 2023, then grew by 17.18% to $531.2 million in 2024, then grew by 9.37% to $562.8 million in 2025.
  • Its last three reported values are $562.8 million in Q3 2025, $544.7 million for Q2 2025, and $501.7 million during Q1 2025.